We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Cancer and Oncology
-
1. Liquid biopsy
- Dr. Fabio Del Ben
-
2. Endometrial cancer: integrating molecular insights into personalized care
- Dr. Gemma Eminowicz
-
5. Latest advances in the development of CAR & TCR T-cell treatments for solid tumours
- Dr. Else Marit Inderberg
-
6. Mode of action of T cells engineered with CAR or TCR for cancer treatment
- Prof. Sebastian Kobold
-
7. Immunotherapy: insights from advanced disease
- Dr. Sara M. Tolaney
-
8. Recent advances in the field of non-coding RNAs in cancer
- Prof. George Calin
- Dr. Maitri Shah
-
9. How tumor-microenvironment interactions drive or inhibit metastasis
- Prof. Isaac P. Witz
-
10. A novel cancer therapy to stimulate oncogenic ERK signalling
- Prof. Reiko Sugiura
-
11. MRD-driven multiple myeloma treatment: next step forward
- Prof. Ola Landgren
-
12. Germinal centre lymphomas: advances in diagnostic and therapeutic intervention
- Dr. Koorosh Korfi
- Prof. Jude Fitzgibbon
-
13. Immunotherapy in lung cancer
- Dr. Mark M. Awad
-
14. Preservation of fertility in cancer patients: the impact of chemotherapy
- Prof. Kutluk H. Oktay
-
16. Solution proposed to a 2000 year old problem in oncology
- Dr. Michael Retsky
- Clinical Practice
-
18. Comprehensive sickle cell care in the era of gene therapy
- Prof. Sophie Lanzkron
-
19. Stillbirth: diagnosis, investigation and aftercare
- Prof. Alexander E. P. Heazell
-
20. Analyzing the medical relevance of skin care trends
- Prof. Zoe Draelos
-
21. Genetic counseling: preconception, prenatal, perinatal
- Prof. Aubrey Milunsky
-
22. The past, present & future of ANA testing: history and challenges of ANA
- Prof. Marvin J. Fritzler
-
23. The past, present & future of ANA testing: changing bandwidth and future of ANA
- Prof. Marvin J. Fritzler
-
25. Mitochondrial diseases: an update
- Dr. Ayesha Saleem
-
26. Hemophilia A
- Dr. Snejana Krassova
-
29. Recent advances in diagnosis and interventions in ophthalmology
- Dr. Rebecca Kaye
- Prof. Andrew Lotery
- Gastroenterology
-
30. Building implantable human liver tissue from pluripotent stem cells
- Prof. David C. Hay
-
31. Microbiome therapies to treat gastrointestinal diseases
- Dr. Patricia Bloom
-
32. Drug-induced liver injury: importance, epidemiology, and mechanisms of DILI
- Prof. James H. Lewis
-
33. Drug-induced liver injury: risk factors and drug development in DILI
- Prof. James H. Lewis
-
34. Drug-induced liver injury: HDS, diagnosing, treating and preventing DILI
- Prof. James H. Lewis
-
35. An update on the multiple faces of celiac disease
- Prof. Aaron Lerner
- Immunology
-
36. Next-generation RNA vaccines
- Dr. Anna Blakney
-
37. Harnessing the immune system for cancer therapy
- Dr. Raghav Sundar
-
38. Rac-enhanced CAR immunotherapy: RaceCAR
- Prof. Denise Montell
-
39. Enhancing innate anti-tumour immunity: lessons from virotherapy and STING agonism 1
- Prof. Kevin Harrington
-
40. Enhancing innate anti-tumour immunity: lessons from virotherapy and STING agonism 2
- Prof. Kevin Harrington
-
41. Drug allergy: new knowledge
- Prof. Mariana C. Castells
-
42. Biologics as a treatment strategy in food allergy
- Prof. Sayantani B. Sindher
-
43. B cells at the crossroads of autoimmune diseases
- Dr. Xiang Lin
-
44. Studying immune responses “one cell at a time”
- Dr. Mir-Farzin Mashreghi
-
45. Mathematical modeling in immunology
- Prof. Ruy M. Ribeiro
-
46. Therapeutic antibody development
- Prof. Dr. Katja Hanack
-
47. Understanding treatment coverage in mass drug administrations
- Dr. Margaret Baker
-
48. The thymus and T cell development: a primer
- Prof. Georg Holländer
- Infectious Diseases
-
50. HCV resistance
- Prof. John Dillon
-
51. The Global Virus Network: collaboration to address pandemic and regional threats
- Prof. Sten H. Vermund
-
52. New concepts in the management of CAP: a focus on severe illness - treatment and therapies
- Prof. Michael S. Niederman
-
53. New concepts in the management of CAP: a focus on severe illness - MRSA and MDR pathogens
- Prof. Michael S. Niederman
-
54. CRISPR-based suppression drives for vector control
- Prof. Andrea Crisanti
-
55. HIV cure: harnessing innate and adaptive strategies
- Prof. Luis Montaner
- Cardiovascular, Metabolism & Nutrition
-
56. Cow’s milk allergy: the future
- Dr. Carina Venter
-
57. Cow's milk allergy: management
- Dr. Carina Venter
-
58. Moving from GWAS hits to functional variants
- Prof. Steve Humphries
-
59. X-linked hypophosphataemia: genetics, diagnosis and management
- Prof. Thomas O. Carpenter
-
60. What is new in type 1 diabetes?
- Prof. Åke Lernmark
-
61. Current concepts for the management of patients with osteoporosis
- Dr. Michael Lewiecki
-
62. Antibodies to control or prevent type 1 diabetes
- Dr. Robert Hilbrands
-
63. Peptide YY (PYY) in obesity and diabetes
- Dr. Nigel Irwin
- Microbiology
-
64. Vaccines and the fight against antimicrobial resistance 1
- Dr. Annaliesa S. Anderson
-
65. Vaccines and the fight against antimicrobial resistance 2
- Dr. Annaliesa S. Anderson
-
66. Vaccines as a weapon against antibiotic resistance
- Dr. Pumtiwitt McCarthy
-
67. PathoLive: pathogen detection while sequencing
- Dr. Simon Tausch
-
69. Successes and failures with vaccines
- Prof. Stanley Plotkin
-
70. Immunology, the microbiome and future perspectives
- Prof. Sheena Cruickshank
-
71. Impact of the HPV vaccine programme – a changing landscape
- Dr. Kevin Pollock
- Neurology and Neuroscience
-
73. Huxley’s science fiction: ion channels in pain, pain resilience, and beyond
- Prof. Stephen Waxman
-
74. Advances in the diagnosis and treatment of tardive dyskinesia
- Prof. Emeritus Stanley N. Caroff
-
75. Cellular therapies for neurological Injuries: bioreactors, potency, and coagulation
- Prof. Charles S. Cox, Jr.
-
76. Cardiovascular involvement in Parkinson’s disease
- Dr. David S. Goldstein
-
77. Current thinking in pain medicine and some thoughts on back pain
- Dr. Nick Hacking
-
78. Bioelectronic medicine: immunomodulation by vagus nerve stimulation
- Prof. Paul Peter Tak
-
79. Developments & future directions in the management of chronic pain
- Prof. Simon Haroutounian
-
80. Deep Brain Stimulation (DBS) neuromodulation for Schizophrenia
- Prof. Judith Gault
-
81. Parkinson’s at 200 years: an update on Parkinson’s research in 2017
- Prof. Patrick A. Lewis
-
82. Alzheimer's disease: where are we up to?
- Prof. John Hardy
- Pharmaceutical Sciences
-
83. Gene manipulation applications in autoimmune diseases 1
- Dr. Leonardo M. R. Ferreira
-
84. Gene manipulation applications in autoimmune diseases 2
- Dr. Leonardo M. R. Ferreira
-
85. Gene manipulation applications in autoimmune diseases 3
- Dr. Leonardo M. R. Ferreira
-
86. Leveraging healthcare data through artificial intelligence
- Prof. Soma Sengupta
-
87. Integration of multi-omics data
- Prof. Ana Conesa
-
88. Bone marrow mesenchymal cells 1
- Prof. Arnold I. Caplan
-
89. Bone marrow mesenchymal cells 2
- Prof. Arnold I. Caplan
-
90. Peptide-drug conjugates as therapeutic modality in drug development 1
- Dr. Syed Faheem Askari Rizvi
-
91. Peptide-drug conjugates as therapeutic modality in drug development 2
- Dr. Syed Faheem Askari Rizvi
-
92. Pharmacokinetics, -dynamics and dosing considerations in children
- Prof. Dr. Karel Allegaert
-
93. Why in vitro permeation test – and not in vivo?
- Prof. Howard Maibach
-
94. The future of plasma-derived medicinal products (PDMP)
- Dr. Daniele Focosi
-
95. RNA therapeutics: clinical applications and methods of delivery
- Prof. John P. Cooke
-
96. Recent advances in the development of gene delivery technologies
- Dr. Takis Athanasopoulos
-
97. Preclinical translation of mesenchymal stem cell therapies
- Dr. Peter Childs
-
98. Modulating gene expression to treat diseases
- Dr. Navneet Matharu
-
99. Accelerating drug discovery with machine learning and AI
- Dr. Olexandr Isayev
-
100. Emerging big data in medicinal chemistry: promiscuity analysis as an example
- Prof. Dr. Jürgen Bajorath
- Dr. Ye Hu
-
101. Binding kinetics in drug discovery
- Dr. Rumin Zhang
-
102. Modeling of antibody-drug conjugate pharmacokinetics
- Dr. Dhaval K. Shah
-
103. Antibody engineering: beginnings to bispecifics and beyond
- Dr. Ian Wilkinson
-
104. Current challenges in the design of antibody-drug conjugates
- Prof. L. Nathan Tumey
-
105. Inorganic nanostructured interfaces for therapeutic delivery
- Prof. Tejal Desai
-
106. Latest development in therapy-related autophagy research
- Dr. Vignir Helgason
- Respiratory Diseases
-
107. Diagnosis of tuberculosis and drug resistant tuberculosis 1
- Dr. Daniela Cirillo
-
108. Diagnosis of tuberculosis and drug resistant tuberculosis 2
- Dr. Daniela Cirillo
-
109. Respiratory syncytial virus vaccination
- Prof. Peter Openshaw
-
110. Advances in gene therapy for respiratory diseases 1
- Prof. John F. Engelhardt
-
111. Advances in gene therapy for respiratory diseases 2
- Prof. John F. Engelhardt
-
112. Asthma
- Prof. William Busse
- Dr. Amanda McIntyre
-
113. New drugs for asthma
- Prof. Peter Barnes
-
114. CompEx asthma: a novel composite exacerbation endpoint
- Dr. Carla A. Da Silva
-
115. Updates in chronic obstructive pulmonary disease (COPD)
- Dr. Omar S. Usmani
- Archived Lectures *These may not cover the latest advances in the field
-
117. AI and big data in drug discovery
- Mr. Ed Addison
-
118. Molecular brain imaging (PET) in diseases with dementia
- Prof. Emeritus Karl Herholz
Printable Handouts
Navigable Slide Index
- Introduction
- Gene manipulation of cell types targeted by immune attack
- Genome editing of human pluripotent stem cells
- Toward a universal stem cell
- Universal cells
- Functional stem cell-derived beta cells (sBC) for therapy
- Human hypoimmune stem cell-derived pancreatic islets avoid rejection and autoimmunity
- Hypoimmune islets achieve insulin independence after allogeneic transplantation
- Study of islet cell transplantation without immunosuppression
- Tour-de-force genome editing of pig embryos to generate xenogeneic organs
- Gene manipulation of cell types targeted by immune attack and immunosuppressive cells to block the immune attack
- Functional sBC for therapy: Challenges
- CAR Tregs for therapy
- Characteristics of a CAR Treg target
- Genetically engineering a unique protein as a CAR target
- Genome engineering to generate EGFRt-expressing human pluripotent stem cells
- EGFRt expression does not affect sBC differentiation
- EGFRt expression does not affect sBC function
- Generating EGFR CAR Tregs
- CAR Tregs are activated by EGFRt-sBCs and secrete inhibitory cytokines
- CAR Tregs suppress T cell proliferation
- CAR Tregs modulate APCs
- CAR Tregs protect EGFRt-sBCs from rejection in vivo
- Insulin, CD3 and FOXP3 expression in the grafts
- Insulin, EGFR and HNA expression in the grafts
- CAR Tregs preserve graft integrity by limiting T cell–mediated destruction
- Making the lock and the key to induce localized immune tolerance
- Off-the-shelf personalized treatment for T1D
- Challenges ahead
- Human iPSC-derived CD4+ Treg-like cells engineered with chimeric antigen receptors
- Off-the-shelf universal treatment for T1D?
- Outstanding questions
- Acknowledgements
- Financial disclosures
Topics Covered
- Gene manipulation of cell types targeted by immune attack
- Universal stem cells
- Human hypoimmune stem cell-derived pancreatic islets
- Functional stem cell-derived beta cells (sBC) for therapy
- CAR Tregs for therapy
Links
Series:
- Gene Manipulation - How and Why?
- Periodic Reports: Advances in Clinical Interventions and Research Platforms
Categories:
Therapeutic Areas:
External Links
Talk Citation
Ferreira, L.M.R. (2026, April 30). Gene manipulation applications in autoimmune diseases 3 [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved May 3, 2026, from https://doi.org/10.69645/NZZY6802.Export Citation (RIS)
Publication History
- Published on April 30, 2026
Financial Disclosures
- Dr. Leonardo M. R. Ferreira is an inventor in provisional and licensed cell and gene therapy patents, a consultant with Guidepoint Global and McKesson, and the founder and CEO of Torpedo Bio.
Gene manipulation applications in autoimmune diseases 3
Published on April 30, 2026
44 min
A selection of talks on Physiology & Anatomy
Transcript
Please wait while the transcript is being prepared...
0:04
Another approach in which
gene manipulation can help with.
autoimmune disease is to
gene-edit the cell types
that are targeted by
the immune attack.
You would do gene editing not on
the immunosuppressive
regulatory T cells,
but on the cells
that are being transplanted
to be protected.
0:26
In this approach, you
can think of either
gene editing primary β cells
or whatever other
cells are needed
for autoimmune diseases,
or you can start with
pluripotent stem cells,
which is easier to
edit their genome and to
grow in unlimited amounts
and then differentiate those
into cells of interest.
This is a field of
universal stem cells or
hypoimmune stem cells.
There's work from
different groups.
We've done some work
in this field as well
and also others.
How does this work?
0:59
One way this works, if
you think about it, is,
well, if T cells see
MHC, if I delete,
if I ablate MHC expression,
then the cells become invisible.
I could make β cells that are
not recognized by T cells,
which seem to be the problem
in diabetes, so let's do that.
One simple way of doing this is
if you knock out the B2M gene,
remember it being the accessory
chain on MHC class 1.
That's why it's relevant here.
If you knock out the B2M gene,
the entirety of MHC
class 1 molecules
is no longer on
the cell surface.
That means that
cytotoxic T lymphocytes
CTLs can no longer
kill these cells.
Now the immune system
is not so easy to fool.
If you have an MHC-negative cell
going around or engrafted
natural killer cells,
which are innate lymphocytes
that are specifically trained,
if you will, to
kill cancer cells,
or rather infected cells,
come and kill the cells.
It turns out that
a lot of viruses
downregulate MHC expression
in infected cells
precisely to evade T
cells and a lot of
cancer cells downregulate the
MHC again to evade T cells.
In this armwrestling evolution,
our body came up with
NK cells to do that.
That's usually good news,
but for us, it makes
our life harder
because now, just simply
making MHC-deficient cells
is not sufficient
to protect them
from immune and
autoimmune attack.
Then we can maybe put in
a molecule to inhibit
the NK cells on top of
heavy notice recognition.
Different molecules exist.
One of them is HLA-G.
HLA-G is a non-classical
MHC molecule dedicated to
suppressing NK
cells in pregnancy.
So at the maternal-fetal
interface fetal trophoblasts
express HLA-G and don't
express HLA and HLA-B.
We're basically mimicking
a fetal trophoblast
in this type of hypommune
universal stem cell.
There are other genes as well.